Busulfan with fludarabine myeloablative conditioning regimen in myeloid neoplasms: A single center experience.

e18000 Background: The best conditioning regimen for patients undergoing myeloablative hematopoietic stem cell transplantation (HSCT) is unknown. Busulfan (Bu) and fludarabine (Flu) containing regimens have shown a good safety profile with low toxicity. A retrospective analysis of patients (pts) with myeloid neoplasms (AML/MDS/CML) who underwent allogeneic HSCT between 2008 and 2012 with myeloablative dose of busulfan and fludarabine is here reported. Methods: A total of 45 pts were included in the analysis. Twenty eight (62.2%) had AML, 15 (33.3%) MDS and 2 CML. The regimen consisted of IV Flu 40 mg/m2 and IV Bu 130 mg/m2 on days -6 to -3. Tacrolimus and methotrexate were used for graft-versus-host (GVHD) prophylaxis. Thymoglobulin (ATG) (4 mg/kg) was administered in unrelated and mismatched donor grafts. All received peripheral blood as source of stem cells. Fourteen donors were HLA identical related, 21matched unrelated and 10 mismatched unrelated. Median age was 58 (range 22-68) with 33 (73%) pts bein...